Daiichi Sankyo has announced its next five-year business plan (FY2026 – FY2030) that outlines how the company plans to deliver more than JPY 2.3 trillion ($14.5 billion) in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 strategic vision. 

The company says that it plans to maximize the value of its antibody drug conjugate (ADC) portfolio and additional oncology pipeline through market penetration of more than 20 new indications across five medicines by 2030, reaching more than 700,000 new patients annually by 2035. 

During FY2026, the company says it is planning five launches across its ADC portfolio in various countries/regions globally, including four new breast cancer indications for Enhertu (fam-trastuzumab deruxtecan-nxki) and Datroway (datopotamab deruxtecan-dlnk), and the company’s first launch in small-cell lung cancer with ifinatamab deruxtecan. The company says it is also advancing research behind new ADCs with novel cytotoxic and immunological payloads. 

Alongside its ADC portfolio, Daiichi Sankyo is further strengthening its R&D focus through what it terms as a “breakthrough generating technology (BGT)” approach, a platform-based drug discovery model. By 2030, Daiichi Sankyo aims to identify additional BGTs, which may consist of multi-specific antibodies, targeted protein degradation, and siRNA. 

Source: Daiichi Sankyo